Travere Therapeutics (TVTX) — AI Analysis & Mentions
TVTX has been discussed in 1 daily market analyses (first mention Jul 23, 2026, latest Jul 23, 2026).
AI Analysis Mentions (1 total)
Travere got a modest but encouraging analyst update. The 12-month price target was raised to $58.71 from $58.36, implying about 4% upside, based on 14 analysts, with a Buy consensus among 15 covering analysts. That is not a huge upside signal, but it does show continued confidence from analysts.